Bridgecreek Investment Management LLC increased its stake in Teladoc, Inc. (NYSE:TDOC) by 50.6% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 91,425 shares of the health services provider’s stock after acquiring an additional 30,725 shares during the quarter. Bridgecreek Investment Management LLC owned about 0.16% of Teladoc worth $3,031,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. UBS Asset Management Americas Inc. acquired a new position in Teladoc in the first quarter valued at approximately $271,000. Parametric Portfolio Associates LLC acquired a new position in Teladoc in the first quarter valued at approximately $1,134,000. American International Group Inc. lifted its stake in Teladoc by 22.2% in the first quarter. American International Group Inc. now owns 14,575 shares of the health services provider’s stock valued at $364,000 after buying an additional 2,644 shares during the period. Teachers Advisors LLC lifted its stake in Teladoc by 53.6% in the first quarter. Teachers Advisors LLC now owns 54,067 shares of the health services provider’s stock valued at $1,352,000 after buying an additional 18,862 shares during the period. Finally, TIAA CREF Investment Management LLC increased its holdings in shares of Teladoc by 57.6% during the first quarter. TIAA CREF Investment Management LLC now owns 95,302 shares of the health services provider’s stock valued at $2,383,000 after acquiring an additional 34,833 shares in the last quarter.

TDOC has been the subject of several recent research reports. Zacks Investment Research downgraded Teladoc from a “hold” rating to a “sell” rating in a report on Monday, July 17th. BidaskClub downgraded Teladoc from a “buy” rating to a “hold” rating in a report on Tuesday, July 25th. Piper Jaffray Companies restated a “buy” rating and set a $42.00 price objective on shares of Teladoc in a report on Friday, July 28th. Cowen and Company restated an “outperform” rating and set a $39.00 price objective (up previously from $36.00) on shares of Teladoc in a report on Thursday, August 3rd. Finally, Cantor Fitzgerald restated a “hold” rating on shares of Teladoc in a report on Monday, August 28th. Five research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $38.17.

In other Teladoc news, CEO Jason N. Gorevic sold 20,000 shares of the company’s stock in a transaction on Monday, October 2nd. The stock was sold at an average price of $33.47, for a total value of $669,400.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Mark Hirschhorn sold 35,000 shares of the company’s stock in a transaction on Tuesday, October 17th. The shares were sold at an average price of $32.84, for a total value of $1,149,400.00. Following the completion of the transaction, the vice president now owns 20,887 shares of the company’s stock, valued at approximately $685,929.08. The disclosure for this sale can be found here. Insiders sold a total of 135,000 shares of company stock valued at $4,408,700 in the last 90 days. Corporate insiders own 4.47% of the company’s stock.

Shares of Teladoc, Inc. (NYSE:TDOC) traded down $0.65 during trading hours on Monday, reaching $29.00. The company’s stock had a trading volume of 699,800 shares, compared to its average volume of 920,063. The company has a quick ratio of 5.08, a current ratio of 5.08 and a debt-to-equity ratio of 0.83. Teladoc, Inc. has a 52-week low of $15.65 and a 52-week high of $37.55.

Teladoc (NYSE:TDOC) last announced its quarterly earnings data on Wednesday, November 1st. The health services provider reported ($0.55) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.25). The business had revenue of $68.70 million during the quarter, compared to the consensus estimate of $67.53 million. Teladoc had a negative net margin of 39.61% and a negative return on equity of 21.59%. The firm’s revenue for the quarter was up 112.0% compared to the same quarter last year. During the same quarter last year, the company earned ($0.33) EPS. equities analysts forecast that Teladoc, Inc. will post -1.57 EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Teladoc, Inc. (TDOC) Position Boosted by Bridgecreek Investment Management LLC” was originally posted by Daily Political and is the property of of Daily Political. If you are viewing this piece on another site, it was illegally copied and republished in violation of United States and international copyright & trademark law. The correct version of this piece can be viewed at https://www.dailypolitical.com/2017/11/13/teladoc-inc-tdoc-position-boosted-by-bridgecreek-investment-management-llc.html.

About Teladoc

Teladoc, Inc is a telehealth company. The Company offers telehealth platform, delivering on-demand healthcare anytime, anywhere, through mobile devices, the Internet, video and phone. The Company’s solution connects its Members, with its over 3,000 board certified physicians and behavioral health professionals treating a range of conditions and cases from acute diagnoses, such as upper respiratory infection, urinary tract infection and sinusitis to dermatological conditions, anxiety and smoking cessation.

Institutional Ownership by Quarter for Teladoc (NYSE:TDOC)

Receive News & Ratings for Teladoc Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc Inc. and related companies with MarketBeat.com's FREE daily email newsletter.